; (B) education to encourage appropriate use; (C) surveillance and monitoring; and (D) stewardship; (3) develop education and communications strategies for educating health care professionals about such product and its appropriate use; and (4) submit to the Food and Drug Administration, beginning at 24 months after the date of approval pursuant to section 505(c) of this Act or section 351(a) of the Public Health Service Act of an application for such product, and every two years thereafter so long as such product is marketed in the United States, an assessment of the sponsor’s stewardship activities relating to such product. (n) Studies (1) Joint study by HHS and GAO (A) In general Beginning 5 years after the date of enactment of the Re-Valuing Anti-Microbial Products Act of 2018 or on the date that the Secretary awards the fifth exclusivity extension period under this section, whichever is earlier, the Director of the Centers for Disease Control and Prevention and Comptroller General of the United States shall conduct a study of the effectiveness of the program under this section for the development of priority antimicrobial products. (B) Contents of the study In conducting the study under subparagraph (A), the Director of the Centers for Disease Control and Prevention and Comptroller General shall examine— (i) the indications and usage for each drug for which an exclusivity extension period was awarded under subsection (a); (ii) the development of resistance to each drug for which an exclusivity extension period was awarded under subsection (a); (iii) the private and societal value of each drug for which an exclusivity extension period was awarded under subsection (a)